Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

(2009) N. Putzki et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study

(2009) Richard K Burt et al.   LANCET NEUROLOGY

Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system

(2008) T. Alexander et al.   BLOOD

Reduced-intensity conditioning in children: a reappraisal in 2008

(2008) I Yaniv et al.   BONE MARROW TRANSPLANTATION

High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis

(2008) Yury L. Shevchenko et al.   EXPERIMENTAL HEMATOLOGY

Autologous haematopoietic stem-cell transplantation in multiple sclerosis

(2008) Gianluigi Mancardi et al.   LANCET NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE